Growth characteristics in children with congenital adrenal hyperplasia

References

1. ↵
   1. Khalid JM,
   2. Oerton JM,
   3. Dezateux C,
   4. Hindmarsh PC,
   5. Kelnar CJ,
   6. Knowles RL

   (2012) Incidence and clinical features of congenital adrenal hyperplasia in Great Britain. Arch Dis Child 97:101–106.

   OpenUrlAbstract/FREE Full Text
2. ↵
   1. Volkl TMK,
   2. Simm D,
   3. Beier C,
   4. Dorr HG

   (2006) Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 117:e98–e105.

   OpenUrlAbstract/FREE Full Text
3. ↵
   1. Ariyawatkul K,
   2. Tepmongkol S,
   3. Aroonparkmongkol S,
   4. Sahakitrungruang T

   (2017) Cardio-metabolic risk factors in youth with classical 21-hydroxylase deficiency. Eur J Pediatr 176:537–545.

   OpenUrl
4. ↵
   1. Charmandari E,
   2. Brook CGD,
   3. Hindmarsh PC

   (2004) Classic congenital adrenal hyperplasia and puberty. Eur J Endocrinol (Suppl 3):U77–U82.
5. ↵
   1. Merke DP,
   2. Cutler GBJ

   (2001) New ideas for medical treatment of congenital adrenal hyper-plasia. Endocrinol Metab Clin North Am 30:121–135.

   OpenUrlPubMedWeb of Science
6. ↵
   1. Eugster EA,
   2. DiMeglio LA,
   3. Wright JC,
   4. Freidenberg GR,
   5. Seshadri R,
   6. Pescovitz OH

   (2001) Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: A meta-analysis. J Pediatr 138:26.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   1. American Academy of Pediatrics

   Obesity and BMI, Available from URL: https://www.aap.org/en-us/about-the-aap/aap-press-room/aap-press-room-media-center/Pages/Obesity-and-BMI.aspx. [cited 2018].
8. ↵
   1. The Royal Children's Hospital Melbourne

   Growth Calculator - Boston Children's Hospital, Available from URL: http://growthcalc.chip.org. [cited 2017].
9. ↵
   1. Finkielstain GP,
   2. Kim MS,
   3. Sinaii N,
   4. Nishitani M,
   5. Van Ryzin C,
   6. Hill SC,
   7. et al.

   (2012) Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 97:4429–4438.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    1. Lin-Su K,
    2. Vogiatzi MG,
    3. Marshall I,
    4. Harbison MD,
    5. Macapagal MC,
    6. Betensky B,
    7. et al.

    (2005) Treatment with growth hormone and luteinizing hormone releasing hormone analog improves final adult height in children with congenital adrenal hyperplasia. The Journal of Clinical Endocrinology & Metabolism 90:3318–3325.

    OpenUrl
11. ↵
    1. Quintos JB,
    2. Vogiatzi MG,
    3. Harbison MD,
    4. New MI

    (2001) 2001. Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 86:1511–1517.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    1. Lin-Su K,
    2. Harbison MD,
    3. Lekarev O,
    4. Vogiatzi MG,
    5. New MI

    (2011) Final adult height in children with congenital adrenal hyperplasia treated with growth hormone. J Clin Endocrinol Metab 96:1710–1717.

    OpenUrlCrossRefPubMed
13. ↵
    1. Hassan MM,
    2. Ibrahim A,
    3. Abdel-Salam A,
    4. Huthail H

    (2013) Growth in infants with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: An analysis of the factors affecting height. Egyptian Pediatric Association Gazette 61:57–62.

    OpenUrl
14. ↵
    1. Young MC,
    2. Hughes IA

    (1990) Response to treatment of congenital adrenal hyperplasia in infancy. Arch Dis Child 65:441–444.

    OpenUrlAbstract/FREE Full Text
15. ↵
    1. Völkl TM,
    2. Simm D,
    3. Beier C,
    4. Dörr HG

    (2006) Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics, 117, doi:10.1542/peds.2005-1005.
16. ↵
    1. Zhang HJ,
    2. Yang J,
    3. Zhang MN,
    4. Liu CQ,
    5. Xu M,
    6. Li XJ,
    7. et al.

    (2010) Metabolic disorders in newly diagnosed young adult female patients with simple virilizing 21-hydroxylase deficiency. Endocrine 38:260–265.

    OpenUrl
17. ↵
    1. Merke DP,
    2. Chrousos GP,
    3. Eisenhofer G,
    4. Weise M,
    5. Keil MF,
    6. Rogol AD,
    7. et al.

    (2000) Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N Engl J Med 343:1362–1368.

    OpenUrlCrossRefPubMedWeb of Science
18. ↵
    1. Sarafoglou K,
    2. Forlenza GP,
    3. Yaw Addo O,
    4. Kyllo J,
    5. Lteif A,
    6. Hindmarsh PC,
    7. et al.

    (2017) Obesity in children with congenital adrenal hyperplasia in the Minnesota cohort: importance of adjusting body mass index for height-age. Clin Endocrinol (Oxf) 86:708–716.

    OpenUrl
19. ↵
    1. Whitaker RC,
    2. Pepe MS,
    3. Wright JA,
    4. Seidel KD,
    5. Dietz WH

    (1998) Early adiposity rebound and the risk of adult obesity. Pediatrics 101:E5.

    OpenUrlCrossRefPubMed
20. ↵
    1. Alqarni SSM

    (2016) A Review of Prevalence of Obesity in Saudi Arabia. Journal of Obesity & Eating Disorders 2:2, doi:10.21767/2471-8203.100025.

    OpenUrl